Huberman LabPsychedelics for Treating Mental Disorders | Dr. Matthew Johnson
At a glance
WHAT IT’S REALLY ABOUT
Inside Psychedelic Therapy: Mechanisms, Risks, Promise, And Future Regulation
- Andrew Huberman interviews Johns Hopkins researcher Dr. Matthew Johnson about how psychedelics such as psilocybin, LSD, DMT, MDMA, ketamine, and others affect the brain, perception, and sense of self, and how those effects can be harnessed therapeutically.
- Johnson explains what qualifies as a psychedelic pharmacologically and experientially, details their action on serotonin and other systems, and contrasts high-dose, guided “macrodose” therapy with popular but unproven microdosing practices.
- They walk through a full psilocybin depression trial from screening and preparation to dosing, monitoring, and post‑session integration, highlighting how profound changes in self‑representation and agency can relieve depression, addiction, and cancer‑related distress.
- The discussion also covers real risks (psychosis, bad trips, unsafe behavior), flashbacks and HPPD, legal and regulatory trends, philanthropy’s role in restarting human research, and early, exploratory ideas about psychedelics for traumatic brain injury and cognitive recovery.
IDEAS WORTH REMEMBERING
5 ideasPsychedelics are best defined by their ability to profoundly alter sense of reality and self, not by a single receptor mechanism.
Johnson distinguishes several pharmacological classes under the “psychedelic” umbrella: classic 5‑HT2A agonists (LSD, psilocybin, DMT, mescaline), NMDA antagonists (ketamine, PCP, dextromethorphan), kappa‑opioid agonists (salvinorin A), and MDMA as an “entactogen.” Despite different receptor targets, they converge experientially in their capacity to radically shift perception, identity, and one’s model of the world.
Therapeutic benefit seems to hinge on profound, guided macrodose experiences that change self‑representation, not on subtle microdoses.
In Johns Hopkins trials, single or few high‑dose psilocybin sessions, embedded in extensive preparation and integration, can produce durable changes in depression, addiction, and cancer‑related anxiety—often lasting many months. Johnson emphasizes that these gains appear linked to deep shifts in how people see themselves (e.g., no longer “I am a smoker” or “I am a failure”) and their sense of agency, not just transient mood elevation.
Microdosing remains largely unsupported by controlled data and may carry underestimated risks if done chronically.
Popular claims that tiny, sub‑perceptual doses enhance creativity, focus, or mood are not borne out by the few double‑blind studies to date, which show little benefit and sometimes mild cognitive impairment (e.g., distorted time estimation). Johnson notes additional theoretical safety concerns: many psychedelics activate 5‑HT2B receptors, implicated in heart‑valve disease with chronic exposure (e.g., fenfluramine/Phen‑fen), so long‑term frequent use could be riskier than assumed.
Set, setting, and structured support are critical both for safety and for translating acute experiences into lasting therapeutic change.
Research protocols involve rigorous psychiatric and cardiovascular screening; several hours of preparatory meetings with two guides; high‑dose psilocybin given in a quiet room with eyeshades and music; continuous monitoring of vital signs; and multiple integration sessions plus written reflection afterwards. Patients are explicitly encouraged to surrender control, fully experience difficult emotions or memories, and later unpack what arose with therapists to convert raw experience into practical life changes.
There are serious but manageable risks—especially for those with psychotic or bipolar vulnerability and for unsupervised high‑dose use.
Johnson stresses that people with schizophrenia, schizoaffective disorder, or bipolar I–type mania (or strong family history) can be destabilized, so such individuals are excluded from trials. “Bad trips” involving extreme fear, loss of self, or dangerous behavior (running into traffic, falls, police encounters) are uncommon but real in uncontrolled settings. In the lab, they mitigate medical risk with screening and protocols (e.g., nitroglycerin if blood pressure spikes) and psychological risk with preparation, reassurance, and a safe environment.
WORDS WORTH SAVING
5 quotesAll of the so‑called psychedelics share the ability to profoundly alter one’s sense of reality—and that often means profoundly altering the sense of self.
— Matthew Johnson
I think of the self as the biggest model—‘I am a thing that’s separate from other things’—and psychedelics can radically change that self‑representation.
— Matthew Johnson
Normally you tell a depressed person, ‘Don’t think of yourself that way,’ and they can’t do it. Under psilocybin, people can actually have an experience where they feel, ‘My God, I can really just decide to change,’ and it sticks.
— Matthew Johnson
Microdosing is the thing everyone talks about, but none of the credible placebo‑controlled studies have shown clear benefits. If anything, we see a little impairment and people feeling a little bit high.
— Matthew Johnson
These can be profoundly destabilizing experiences. That’s why screening, preparation, and the right container matter so much—anyone can have a bad trip if you push the dose high enough in the wrong environment.
— Matthew Johnson
High quality AI-generated summary created from speaker-labeled transcript.
Get more out of YouTube videos.
High quality summaries for YouTube videos. Accurate transcripts to search & find moments. Powered by ChatGPT & Claude AI.
Add to Chrome